Diretrizes Brasileiras para o tratamento farmacológico de pacientes hospitalizados com COVID-19: Diretriz conjunta da Associação Brasileira de Medicina de Emergência, Associação de Medicina Intensiva Brasileira, Associação Médica Brasileira, Sociedade Brasileira de Angiologia e Cirurgia Vascular, Sociedade Brasileira de Infectologia, Sociedade Brasileira de Pneumologia e Tisiologia e Sociedade Brasileira de Reumatologia

Falavigna, Maicon; Stein, Cinara; Amaral, José Luiz Gomes do; Azevedo, Luciano Cesar Pontes de; Belli, Karlyse Claudino; Colpani, Verônica; Cunha, Clóvis Arns da; Dal-Pizzol, Felipe; Dias, Maria Beatriz Souza; Ferreira, Juliana Carvalho; Freitas, Ana Paula da Rocha; Gräf, Débora Dalmas; Guimarães, Hélio Penna; Lobo, Suzana Margareth Ajeje; Monteiro, José Tadeu; Nunes, Michelle Silva; Oliveira, Maura Salaroli de; Prado, Clementina Corah Lucas; Santos, Vania Cristina Canuto; Silva, Rosemeri Maurici da; Sobreira, Marcone Lima; Veiga, Viviane Cordeiro; Vidal, Ávila Teixeira; Xavier, Ricardo Machado; Zavascki, Alexandre Prehn; Machado, Flávia Ribeiro; Carvalho, Carlos Roberto Ribeiro de.
Rev. bras. ter. intensiva ; 34(1): 1-12, jan.-mar. 2022. tab, graf
Artigo em Português | LILACS, BIGG | ID: biblio-1388050

Documentos relacionados

  1. Long-term (180-Day) Outcomes in Critically Ill Patients With COVID-19 in the REMAP-CAP Randomized Clinical Trial.
  2. Hospital compounding to face shortage: A case study of the development of a lopinavir-ritonavir oral suspension during the first wave of SARS-COV-2 in France.
  3. Lopinavir-ritonavir alone or combined with arbidol in the treatment of 73 hospitalized patients with COVID-19: A pilot retrospective study.
  4. Early administration of lopinavir/ritonavir plus hydroxychloroquine does not alter the clinical course of SARS-CoV-2 infection: A retrospective cohort study.
  5. Molnupiravir in COVID-19: A Scoping Review.
  6. Should RECOVERY have used response adaptive randomisation? Evidence from a simulation study.
  7. Effect of Arbidol (Umifenovir) on COVID-19: a randomized controlled trial.
  8. Efficacy and safety of favipiravir plus interferon-beta versus lopinavir/ritonavir plus interferon-beta in moderately ill patients with COVID-19: A randomized clinical trial.
  9. Safety of hydroxychloroquine and darunavir or lopinavir in COVID-19 infection.
  10. Favipiravir, lopinavir-ritonavir, or combination therapy (FLARE): A randomised, double-blind, 2 × 2 factorial placebo-controlled trial of early antiviral therapy in COVID-19.